Sep 26, 2019 14:21 JST

Source: Eisai

Eisai and Tokio Marine Nichido Enter Into Business Alliance for Co-Existence and Prevention of Dementia

TOKYO, Sep 26, 2019 - (JCN Newswire) - Eisai Co., Ltd. and Tokio Marine & Nichido Fire Insurance Co., Ltd. announced today that the companies have entered into a business alliance agreement for co-existence and prevention of dementia.

Under this agreement, the following initiatives are scheduled: (1) "disease awareness initiatives" to dispel the misunderstandings and assumptions and to attempt for a widespread correct understanding of dementia, (2) "environment development" to implement the self-assessment of cognitive function on a daily basis, and (3) "measures to familiarize insurance product" to support people with dementia so they can continue to live their own lives. Eisai and Tokio Marine Nichido will work towards co-existence and prevention of dementia by mutually utilizing Eisai's abundant experience and knowledge of medicine creation and disease awareness activities in the field of dementia as well as Tokio Marine Nichido's expertise and networks cultivated in its insurance products and related services.

As part of dementia disease awareness activities, Eisai and Tokio Marine Nichido today began distribution of the booklet "Wakaru to Kawaru Ninchisho - What is Dementia?" that was co-produced based on Eisai's dementia experience and expertise.

This booklet simply summarizes the symptoms and types of dementia and progression of Alzheimer's disease. In addition, it includes interviews with specialists and medical staff about the images of dementia and the daily life of patients and their families living with dementia.

"Misunderstandings and assumptions, such as people with dementia can't understand anything or they are not themselves once they devlop dementia, create the impression that dementia is terrible and misery. I hope this booklet will help educate people about the the reality of dementia by prodiving accurate information and dispelling misperceptions," said Dr. Manabu Ikeda, Professor, Department of Psychiatry, Osaka University Medical School, who supervised this booklet.

The booklet for dementia disease awareness will be serialized and issued continuously.

With the rapid aging of the population, it is predicted that one out of five elderly people over the age of 65 will have dementia in Japan. The "Outline for Promoting the Dementia Plan" was compiled by the government in June this year. The dementia barrier-free efforts are aimed at co-existence so that those with dementia can continue living the way they want in the communities they are used to living. The initiatives for prevention based on the co- existence foundation are expected to make significant progress.

Eisai and Tokio Marine Nichido will collaborate on initiatives for co-existence and prevention of dementia, including dementia disease awareness initiatives. The copmanies aim to contribute to the realization of the well-being of people with dementia and their families by considering collaboration with other companies and organizations that agree with the purpose of Eisai and Tokio Marine Nichido.

About Tokio Marine & Nichido Fire Insurance Co., Ltd.

Tokio Marine & Nichido Fire Insurance Co., Ltd. has provided a variety of insurance products and the related services to support the challenges of all individual and corporate customers. In the field of dementia, we are advancing initiatives such as development and launch of the industry's first "Ninchisho Anshin Plan" which is an exclusive insurance for people with dementia and their families.

We will also utilize technologies to further enhance the "power of insurance" and promote its penetration "wholeheartedly" as we strive to support people and corporations that take on challenges, thereby contributing to resolving social issues in Japan.

For further information on Tokio Marine & Nichido Fire Insurance Co., Ltd., please visit https://www.tokiomarine- nichido.co.jp.

Contact:
Media Inquiries:
Eisai Co., Ltd.
Public Relations Department 
TEL: +81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
September 17 2025 17:20 JST
 
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
September 12 2025 12:20 JST
 
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
September 08 2025 16:49 JST
 
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
September 04 2025 09:56 JST
 
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
September 03 2025 10:32 JST
 
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
September 01 2025 12:44 JST
 
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
August 29 2025 17:17 JST
 
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
August 25 2025 18:30 JST
 
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
August 18 2025 08:11 JST
 
Revenue of LEQEMBI(R) (Preliminary Basis)
July 31 2025 17:27 JST
 
More Press release >>

Latest Press Release


More Latest Release >>